# MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

> **NCT03853616** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Miltenyi Biomedicine GmbH** · enrollment: 48 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia Recurrent
- B-cell Lymphoma Recurrent
- B-cell Lymphoma Refractory
- Chronic Lymphocytic Leukemia Recurrent
- Chronic Lymphocytic Leukemia Refractory

## Interventions

- **BIOLOGICAL:** MB-CART19.1

## Key facts

- **NCT ID:** NCT03853616
- **Lead sponsor:** Miltenyi Biomedicine GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-26
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03853616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03853616, "MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03853616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*